Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today reported financial results and corporate updates for the first half of 2010.

Group revenues grew significantly by 33% to € 25.0 m (2009: € 18.7 m), driven by multiple milestone achievements and strong growth in Evotec's drug discovery alliances. The gross margin was strong at 45.1% (2009: 37.6%). R&D expenses declined by 82% to € 2.9 m (2009: € 16.3 m), and SG&A costs by 15% to € 7.7 m (2009: € 9.0 m). On this basis, supported by the high margin milestone income, Evotec's operating result for the first half of 2010 was positive at € 0.3 m (2009: € 29.1 m loss). Liquidity including cash, cash equivalents and investments at the end of June 2010 amounted to € 67.9 m.

Based on this strong H1 2010 operational performance, Evotec raised its revenue guidance for the fiscal year 2010 published on 25 March 2010: Total Group revenues are now expected to grow by more than 20%, leading to revenues of € 52 to 54 m (before: € 48 to 50 m). All other financial targets remain unchanged. Despite € 2 m cash to be used in the acquisition of DeveloGen, mainly for DeveloGen working capital needs, Evotec also confirms its 2010 year-end liquidity target of > € 64 m at constant year-end 2009 currencies. This strongest half year in the Company's history represents a solid foundation to develop Evotec to sustainable profitability latest in 2012.

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Schnackenburgallee 114, 22525 Hamburg, Germany, phone: +49.(0)40.560 81-242, e-mail: werner.lanthaler@evotec.com